Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06829524 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

HANDLE-a Real World Study on Satralizumab in NMOSD

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened
    • Secondary endpoints: details revised at 1 of 4 entries
    • Site details revised
    • Eligibility criteria expanded, about 5 words
  2. Primary completion date: Aug 26, 2026 to Mar 31, 2027
    • Start date: Feb 26, 2025 to Mar 31, 2025
    • Study completion date: Jan 26, 2027 to Jun 30, 2027
    v3
  3. Secondary endpoints: details revised at 1 of 4 entriesv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a single-center, retrospective-prospective, non-interventional cohort study to assess the clinical outcomes of Chinese NMOSD patients treated with satralizumab in a real-world patient management model by collecting follow-up data in clinical practice.
Trial Details
NCT Number NCT06829524
Lead Sponsor Huashan Hospital
Conditions
(from sponsor)		 Neuromyelitis Optica Spectrum Disorders (NMOSD)
Related terms Neuromyelitis Optica
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov